Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brimonidine - Allergan

Drug Profile

Brimonidine - Allergan

Alternative Names: AGN 190342; AGN 190342LF; Aiphagan Ophthalmic Solution 0.1%; Alphagan; Alphagan P; Alphagan Z; Brimonidine tartrate; DE 087; SNJ-2022; UK 1430 18; UK 14304

Latest Information Update: 05 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Allergan; Senju Pharmaceutical
  • Class Antiglaucomas; Antihypertensives; Imidazoles; Quinoxalines; Skin disorder therapies; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension
  • Phase II Dry age-related macular degeneration
  • No development reported Retinal detachment; Retinitis pigmentosa
  • Discontinued Neurological disorders

Most Recent Events

  • 30 Oct 2018 Efficacy data from the phase II BEACON trial in Dry age-related macular degeneration released by Allergan
  • 30 Oct 2018 Allergan plans a phase III trial for brimonidine intravitreal implant in geographic atrophy due to age-related macular degeneration, in the second half of 2019
  • 31 Aug 2018 Brimonidine terminates phase II trials in Dry age-related macular degeneration in USA, Australia, France, Germany, Italy and United Kingdom (Intravitreous) (NCT02087085)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top